Viking Bolsters MASH Case With 52-Week Histology Data
Viking will look to plan a Phase III program with the FDA after showing 52-week success on MASH resolution and fibrosis reduction with VK2809. The firm still hopes to move forward with a partner.
Viking will look to plan a Phase III program with the FDA after showing 52-week success on MASH resolution and fibrosis reduction with VK2809. The firm still hopes to move forward with a partner.